Supreme Court narrows patent risk for skinny-label generics
The Supreme Court unanimously ruled Hikma Pharmaceuticals did not infringe Amarin's patents in a skinny-label case, shielding generic manufacturers from certain patent lawsuits and paving the way for more affordable generics while overturning a lower court ruling.
